Roux C. First National ODISSEE Meetings (Osteoporosis: DIagnosis and Surveillance of SEvErity) Managing Severe Osteoporosis: from Diagnosis to Treatment. Joint Bone Spine 2010, 77(Suppl 2):S101-S102.
Thomas T. Male osteoporosis and glucocorticoid-induced osteoporosis 2nd National ODISSEE Meetings (Osteoporosis: DIagnosis and Surveillance of SEvErity). Joint Bone Spine 2011, 78(Suppl 2):S189.
Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 2009, 79:S1-S130. KDIGO.
Levin A., Bakris G.L., Molitch M., et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007, 71:31-38.
Vassalotti J.A., Uribarri J., Chen S.C., et al. Trends in mineral metabolism: Kidney Early Evaluation Program (KEEP) and the National Health And Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis 2008, 51:S56-S58.
K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003, 42:S1-S201.
Gauci C., Moranne O., Fouqueray B., et al. Pitfalls of measuring total blood calcium in patients with CKD. J Am Soc Nephrol 2008, 19:1592-1598.
Sarah Cheriet, Matthieu Royer, Gérald Rajzbaum, et al. Vitamin D Supplementation in Patients with Chronic Kidney Disease?. Joint Bone Spine Suppl oct 2012.
Nussbaum S., Zahradnik R., Lavigne J., et al. Highly sensitive twosite immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 1987, 33:1364-1367.
Lepage R., Roy L., Brossard J.H., et al. A non (1-84) circulating parathyroid hormone fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem 1998, 44:805-809.
Slatopolsky E., Finch J., Clay P., et al. A novel mechanism for skeletal resistance in uremia. Kidney Int 2000, 58:753-761.
Gao P., Scheibel S., D'Amour P., et al. Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: implication for improvement of accurate assessment of parathyroid function. J Bone Miner Res 2001, 16:605-614.
Sherrard D.J., Hercz G., Pei Y., et al. The spectrum of bone disease in end-stage renal failure an evolving disorder. Kidney Int 1993, 43:436-442.
Barretto F.C., Barreto D.V., Moyses R.M., et al. K/DOQI-recommended intact PTH levels do not prevent low turnover bone disease in hemodialysis patients. Kidney Int 2008, 73:771-777.
Block G.A., Klassen P.S., Lazarus J.M., et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. A Am Soc Nephrol 2004, 15:2208-2218.
Kalantar-Zadeh K., Kuwae N., Regidor D.L., et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006, 70:71-78.
Souberbielle J.C., Boutten A., Carlier M.C., et al. Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int 2006, 70:345-350.
Cavalier E., Delanaye P., Vranken L., et al. Interpretation of serum PTH concentrations with different kits in dialysis patients according to the KDIGO guidelines: importance of the reference (normal) values. Nephrol Dial Transplant 2012, 27:1950-1956.
